Trial Profile

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 02 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favipiravir (Primary) ; Chloroquine
Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use

Most Recent Events

01 Mar 2021 Primary endpoint (Need for mechanical ventilation) has not been met as per results published in the Archives of Virology.
01 Mar 2021 Primary endpoint (Number of patients with mortality) has not been met as per results published in the Archives of Virology.
01 Mar 2021 Status changed from recruiting to completed, as per results published in the Archives of Virology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com